Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy is Well Tolerated in a Pilot Study of Immunocompromised Patients With Influenza A

EMERYVILLE, Calif., April 28 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.